<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2208210963
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MICROLUT 0.03MG-TAB COATED TAB.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVONORGESTREL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        35
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAYER AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 392]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-KAMAL IMPORT OFFICE CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03AC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Microlut is a hormonal contraceptive belonging to the group of the so-called minipills. In contrast<br />to &lsaquo;combined Pills&raquo; (combined oral contraceptives), that contain two hormones, an estrogen and a<br />progestogen (gestagen), minipills contain only one progestogen, and that in a low dose.<br />Microlut is used for contraception.<br />Children<br />Microlut must not be used before the menarche.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Microlut,<br />R if you are allergic to levonorgestrel or one of the other components of this pharmaceutical listed in<br />section 6,<br />R if you are pregnant or suspect you are,<br />R if there is a blood clot in the veins, e.g. in a leg (deep venous thrombosis) or in the lungs (pulmonary<br />embolism) (see also &laquo;The minipill and thrombosis&raquo;),<br />R if arterial vascular disease is present or in history, e.g. myocardial infarction, cerebrovascular accident,<br />ischemic heart disease (angina pectoris) (see also &laquo;The minipill and thrombosis&raquo;),<br />R if you have sugar diabetes, which has caused vascular changes,<br />R if you now have or have a history of severe hepatic disease and your liver values have not yet returned<br />to normal,<br />R if you have or have had a benign or malignant liver tumor,<br />R if you have or have had a sex hormone-dependent malignancy, such as breast cancer or genital<br />cancer, or if you suspect that you have any of these diseases,<br />R if you have undiagnosed vaginal bleeding,<br />If any of the above cases occurs while you are taking Microlut, you must stop taking the drug<br />immediately and see your doctor. In the meantime, you should use a different, non-hormonal<br />contraceptive method. For further information, see also &laquo;Warnings and precautions&raquo;.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking<br />This section describes when you must immediately stop taking the minipill or when the reliability of the<br />minipill might be impaired. In these cases, you are advised either not to have sexual intercourse or to<br />use other, non-hormonal contraceptive methods, such as condoms or another barrier method. However,<br />it is advisable not to use the calendar or temperature methods. These methods can fail, because taking<br />the minipill alters the monthly fluctuations in body temperature and the uterine mucosa.<br />Like all oral contraceptives, Microlut does not offer any protection against HIV infection (AIDS) or other<br />sexually transmitted diseases.<br />Medical examination/checkup<br />Before you start or resume taking Microlut, a full history must be taken of the diseases you and your<br />close relatives have had, and pregnancy must be ruled out. The medical examination (including pelvis<br />and breast) should reflect this medical history, as well as the contraindications and warnings relevant<br />to this medicinal product. During the course of treatment, regular check-ups are recommended, the<br />frequency and nature of which should be adapted to your individual state of health. Investigations,<br />including your breasts (mammography), are to be conducted in line with current preventive care and<br />according to your personal health status.<br />You require special medical monitoring, if<br />R you have only one fallopian tube, have or have had an inflammation of the fallopian tubes or a tubal<br />(ectopic) pregnancy (see &laquo;The minipill and tubal (ectopic) pregnancy&raquo;)<br />R you smoke (see &lsquo;The minipill and thrombosis&raquo;),<br />R you have sugar diabetes (see &laquo;The minipill and other diseases&raquo;)<br />R you are seriously overweight (body mass index above 30 kg/m2; see &laquo;The minipill and thrombosis&raquo;)<br />R you or a close relative had a venous occlusion (at an early age) (see &laquo;The minipill and thrombosis&raquo;)<br />R you have high blood pressure (see &lsquo;The minipill and other diseases&rsquo;)<br />R breast cancer occurred in close relatives (see &laquo;The minipill and cancer&raquo;)<br />R you have a liver condition (see &laquo;The minipill and cancer&raquo; and &laquo;The minipill and other diseases&raquo;)<br />R you have a tendency toward pigmentation spots (see &lsquo;The minipill and other diseases&rsquo;)<br />The minipill and thrombosis<br />The term thrombosis refers to the formation of a thrombus (blood clot), that is capable of blocking<br />a blood vessel. Thromboses occur in such places as the deep veins of the lower leg (deep venous<br />thrombosis). If one of these blood clots becomes dislodged, it can be carried through the bloodstream<br />into the lung arteries, obstructing a blood vessel there (pulmonary embolism). Deep venous thromboses<br />in the legs are rare. They can occur regardless of whether you are taking the minipill or not. They can<br />also occur during pregnancy.<br />A thrombosis does not always heal completely and sometimes results in lasting disabilities. A<br />thrombosis can even be fatal.<br />Large-scale investigations point to a correlation between the use of &lsquo;combined pills&rsquo; and a more frequent<br />occurrence of deep venous thromboses of the leg, other deep venous thromboses and pulmonary<br />embolisms. The thrombosis risk is somewhat higher in women taking these drugs than in those women<br />who do not use the &lsquo;combined pill&rsquo; for contraception. The significance of these findings for minipills, like<br />Microlut, is not clear.<br />It is known that the risk of suffering a venous thromboembolism increases with age. Moreover, the risk<br />increases, if you are seriously overweight (body mass index above 30 kg/m2) or if you or a close relative<br />of yours (sibling or parents at a relatively early age) had a venous thromboembolic disorder.<br />The risk of deep venous thrombosis of the leg may be temporarily enhanced if you undergo surgery, are<br />strictly confined to bed or immobilized (e.g. if a leg is in a cast). In this event, you should inform your<br />doctor as early as possible that you are taking the minipill. Your doctor will then advise you to stop<br />taking the minipill several weeks prior to the operation, at the start of bed rest or immobilization. Your<br />doctor will also tell you when you can resume taking the minipill after remobilization.<br />Equally, the risk of a blood clot may increase following childbirth.<br />A thrombosis can also occur in an artery (arterial thrombosis), e.g. in the coronary arteries or the arteries<br />supplying the brain, and consequently result in myocardial infarction or stroke. Clinical observation<br />studies showed very few signs of any link between the use of the minipill and an enhanced risk of<br />suffering a myocardial infarction or stroke. Known risk factors for the occurrence of such conditions<br />are increasing age, hypertension and smoking. The risk of suffering a stroke might be slightly higher in<br />women with high blood pressure taking the minipill.<br />If high blood pressure occurs while you are taking Microlut, you might be advised to stop taking the<br />drug and to use a different contraceptive method.<br />The following symptoms can be signs of venous or arterial thrombosis. If you notice any of these<br />symptoms in yourself, stop taking the tablets immediately and see a doctor, right away:<br />R unusual pain or swelling in a leg,<br />R pain and tightness in the chest, possibly radiating into the left arm,<br />R sudden difficulty in breathing,<br />R sudden, severe coughing,<br />R unusual, strong or persistent headaches,<br />R sudden partial or complete loss of vision,<br />R seeing double,<br />R indistinct speech or problems with speaking,<br />R dizziness,<br />R collapse, possibly in connection with an epileptic seizure,<br />R sudden weakness or numbness on one side of the body or in one part of the body,<br />R problems with movement (motor disturbances),<br />R severe, intolerable abdominal pain.<br />The minipill and cancer<br />Breast<br />Breast cancer is diagnosed slightly more often in women who are currently using the &lsquo;combined pill&rsquo;<br />than in women of the same age who do not use combined oral contraceptives. It is not known, whether<br />this is caused by the &lsquo;combined pill&rsquo;. The difference may be due to the fact that women who take the<br />&lsquo;combined pill&rsquo; get examined more frequently and thoroughly, so that breast cancer is discovered earlier.<br />The difference can also be the result of a combination of both.<br />Because breast cancer is rare in women under 40 years of age, the excess number of breast cancer<br />diagnoses in current and recent users of &lsquo;combined pills&rsquo; is small in relation to the overall risk of breast<br />cancer.<br />This number of breast cancer diagnoses gradually levels out and after 10 years, there is no ascertainable<br />difference between previous &lsquo;combined pill&rsquo; users and other women. This risk for women taking the<br />minipill is about the same as for those taking &lsquo;combined pills&rsquo;, even though the data collected for the<br />minipill is less conclusive.<br />The breast cancers diagnosed in ever-users tend to be less advanced clinically than the cancers<br />diagnosed in never-users.<br />Liver<br />In rare cases, benign liver tumors, and even more rarely, malignant liver tumors have been reported in<br />users of &lsquo;combined pills&rsquo;. In isolated cases, these tumors have led to life-threatening intra-abdominal<br />hemorrhages. If you suddenly have severe abdominal pain, you must see your doctor, right away.<br />Psychiatric conditions:<br />Some women using hormonal contraceptives such as Microlut have reported depression or depressed<br />mood. Depression can be serious and may occasionally lead to suicidal thoughts. If you experience mood<br />swings or depressive symptoms, contact your doctor for further medical advice as soon as possible.<br />The minipill and other diseases<br />The minipill generally does not appear to affect blood pressure in healthy women. However, if a<br />sustained hypertension develops during the use of Microlut, it is advisable to discontinue Microlut.<br />Occurrence of full-body itching (cholestatic pruritus) or blockage of bile drainage (cholestatic icterus)<br />necessitates the discontinuation of Microlut. Particular caution is required, if these disorders have<br />already occurred during pregnancy or previous use of hormones.<br />If you are diabetic, the required dose of the medicinal products used to treat your diabetes (diabetes<br />mellitus) may change while taking Microlut. Diabetic women, also those with a history of gestational<br />diabetes mellitus, should therefore be carefully observed while taking Microlut, especially during the<br />initial stages of use.<br />Yellowish-brown pigmentation spots may occasionally occur, especially in women with a history of<br />chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or<br />ultraviolet radiation (e.g. sun tanning equipment) while taking Microlut.<br />The minipill and tubal (ectopic) pregnancy<br />In those exceptional cases when a woman becomes pregnant while taking the minipill, the pregnancy is<br />more likely to be tubal (ectopic) than are pregnancies among users of the &lsquo;combined pill&rsquo;.<br />Therefore, in women with a history of tubal (ectopic) pregnancy, of ovaritis or who have only one<br />fallopian tube, Microlut should be used only after careful risk/benefit assessment by a doctor.<br />If lower abdominal complaints occur together with an irregular cycle pattern (no bleeding (amenorrhea)<br />or a stretch of time without bleeding (amenorrhea) followed by persistent bleeding), an extrauterine<br />pregnancy must be considered. If this happens, you must see your doctor at once.<br />The minipill and persistent ovarian cysts<br />Persistent ovarian follicles (persistent follicles are often referred to as functional ovarian cysts) may<br />occur during the use of the minipill. Most of these follicles are asymptomatic, although some may be<br />accompanied by pelvic pain or painful sexual intercourse (dyspareunia). In most cases, the enlarged<br />follicles disappear spontaneously during two to three months of observation.<br />In the following cases you should see your doctor as soon as possible<br />R changes in your health, e.g. occurrence of conditions described elsewhere in these instructions for use<br />(see &laquo;Do not take Microlut&raquo;, and &laquo;Warnings and precautions&raquo;, also consider any disorders, that have<br />occurred in your close relatives),<br />R lumps in the breast,<br />R persistent or increased irregular bleeding,<br />R if you forgot to take tablets or took them late and had sexual intercourse,<br />R if your menstrual bleeding does not occur within six weeks after your last menstrual bleeding (only<br />start a new blister pack when it is certain that you are not pregnant),<br />R if you have unexplained lower abdominal complaints together with an irregular cycle pattern<br />(menstrual bleeding does not occur (amenorrhea) or if bleeding fails to occur (amenorrhea) followed<br />by irregular bleeding, see &laquo;The minipill and tubal (ectopic) pregnancy&raquo;),<br />R if you notice possible signs of a thrombosis (see &laquo;The minipill and thrombosis&raquo;).<br />Reduced efficacy<br />The efficacy of Microlut can be impaired in the event of<br />R one or multiple missed or late tablets (see &laquo;If you forget to take Microlut&raquo;),<br />R vomiting and/or severe diarrhea (see &laquo;If you suffer from vomiting and/or diarrhea&raquo;),<br />R concomitant medication (see &laquo;Taking Microlut with other medicines&raquo;).<br />If Microlut and products containing St. John&rsquo;s wort are taken at the same time, it is advisable to use an<br />additional barrier contraceptive method (see &lsquo;Taking Microlut with other medicines&rsquo;).<br />Reduced cycle control<br />P Menstrual bleeding<br />Menstrual bleeding occurs at normal intervals and is of normal duration and intensity in the majority of<br />cases while taking the minipill. However, both shortened and lengthened intervals are observed.<br />These changes mainly occur in the initial months of use. The bleeding pattern then becomes steady<br />during the course of further use, establishing a personal menstrual rhythm in most cases. You should<br />always record bleeding in a calendar.<br />P Procedure in the event of intermenstrual bleeding<br />Intermenstrual bleeding of varying intensity may occur, particularly during the first few months. This is<br />not a medical reason to stop taking Microlut. You should, however, inform your doctor so that organic<br />causes for such bleeding can be ruled out.<br />P Absence of menstrual bleeding<br />Absence of menstrual bleeding (amenorrhea) may occur, in most cases only for one or two menstrual<br />periods. In rare cases, bleeding may fail to occur for longer intervals.<br />If no menstrual bleeding has occurred within 6 weeks after the last menstrual bleeding, see your doctor<br />so that pregnancy can be excluded before tablet taking is continued.<br />Additional information for particular patient groups<br />Use in children and adolescents<br />Microlut is not suited for use before the first monthly period (menarche).<br />Elderly women<br />Microlut is not suited for use after menopause.<br />Women with impaired liver function<br />Do not take Microlut if you suffer from severe liver disorders. See also sections &lsquo;Do not take Microlut&rsquo; and<br />&lsaquo;Warnings and precautions&rsaquo;.<br />Taking Microlut with other medicines<br />Please inform your doctor or pharmacist if you are taking/using or have recently taken/used any other<br />medicines or are planning to take/use any other medicines, even those not prescribed. Also inform any<br />other doctor or dentist who prescribes you other medicines (or the pharmacist) about the fact that you<br />are taking Microlut. They can then tell you whether you need to use additional precautionary birth<br />control methods and, if yes, for how long.<br />Please note, that this information can also apply to medicines that you have used recently.<br />Some medicines<br />R may influence the blood levels of Microlut<br />R decrease the contraceptive efficacy of the minipill<br />R may result in unexpected bleeding.<br />Among them are:<br />R drugs used in treating:<br />P epilepsy (e.g., primidone, phenytoin, barbiturates, carbamazepine, oxcarbazepine, topiramate,<br />felbamate)<br />P tuberculosis (e.g., rifampicin)<br />P HIV and hepatitis C virus infections (so-called protease inhibitors and non-nucleoside reverse<br />transcriptase inhibitors)<br />P fungal diseases (e.g. griseofulvin, azole antifungal drugs, e.g., fluconazole, itraconazole,<br />ketoconazole, voriconazole)<br />P bacterial infections (macrolide antibiotics, e.g., clarithromycin, erythromycin)<br />P specific heart diseases, high blood pressure (calcium channel blockers, e.g., verapamil, diltiazem)<br />R the herbal medicine St. John&rsquo;s wort (primarily used to treat depression)<br />R grapefruit juice.<br />If you need to take such drugs for longer periods, please ask your primary care physician for advice.<br />When considered necessary, you should use a different, non-hormonal contraceptive method.<br />The minipill may influence the effect of other drugs. Accordingly, plasma and tissue concentrations may<br />increase (e.g. cyclosporin, a drug used to prevent organ transplant rejections).<br />Note: You should refer to the instructions for use of the respective concomitant medication to identify<br />any possible interactions.<br />Laboratory tests<br />Inform your doctor or the laboratory staff that you are taking Microlut if you have to have a blood test<br />or other laboratory tests done as its use may influence the results of some tests.<br />Pregnancy and breast-feeding<br />Pregnancy<br />If you are pregnant or breast-feeding or think you may be pregnant, you must not take Microlut. If you<br />become pregnant whilst taking Microlut, immediately stop taking it and see your doctor.<br />Undesired hormonal effects on the development of genitourinary organs cannot be completely ruled<br />out, but most of the scientific studies carried out to date have revealed neither an increased risk of birth<br />defects in children born to women who used contraceptives prior to pregnancy, nor a teratogenic effect<br />when progestogens have been taken inadvertently during pregnancy at doses, like those contained in<br />Microlut.<br />Breast-feeding<br />The minipill is considered to comprise the next choice category after non-hormonal methods.<br />There appears to be no adverse effects on infant growth or development when using the minipill after<br />six weeks postpartum. The minipill does not appear to affect the quantity or quality of breast milk,<br />however, minute amounts of the active substance are excreted with the milk.<br />Effects on ability to drive and use machines<br />No special precautions are necessary.<br />Microlut contains sugar (sucrose) and milk sugar (lactose).<br />Please, take Microlut only after consulting with your doctor, if you know that you suffer from an<br />intolerance of certain sugars.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicinal product exactly as your doctor has told you. You should check with your<br />doctor or pharmacist if you are not sure.<br />Method of administration<br />This medicinal product is to be taken orally.<br />You should take the tablets whole (do not chew) with sufficient liquid (preferably with a glass of water).<br />The usual dose is<br />1 tablet daily.<br />Microlut is taken continuously, i.e. without any break.<br />This means that, after the first pack has been finished, the next should be started without interruption.<br />Microlut must be taken at the same time each day, continuously, without any break, without regard to<br />bleeding (menstrual bleeding or even intermenstrual bleeding).<br />The attempt should always be made to maintain an interval of exactly 24 hours between tablets. This<br />interval should by no means be exceeded by more than 3 hours, otherwise protection against conception<br />may be at risk. The greatest possible reliability of Microlut can be assured only by adhering as closely as<br />possible to the 24-hour-intervals.<br />When to start taking the pill from the first blister pack<br />R If you did not take a contraceptive &lsquo;Pill&rsquo; last month:<br />Start taking Microlut on day 1 of your natural cycle, i.e. the first day of your menstrual bleeding.<br />Start taking the tablets by removing the first tablet from the field of the calendar pack, marked with<br />the abbreviated day of the week (e.g. &laquo;Mo&raquo; for Monday). Take the rest of the pills in the direction of the<br />arrow on the blister pack continuously for 35 days, until the blister pack has been used up. Then, start<br />taking the tablets from the next blister pack on the very next day.<br />If you start taking Microlut later than on the first day of menstruation, an additional barrier method<br />of contraception is to be used during the first seven days. If you proceed as described earlier, however,<br />contraception is guaranteed from the start of tablet taking.<br />R Switching from a &lsaquo;combined pill&rsaquo;, a vaginal ring or a contraceptive patch:<br />If you have always taken the &lsquo;previous pill&rsquo; correctly and consistently, you should start taking Microlut<br />immediately on the day after you take the last hormone-containing tablet (or, if you take a &lsquo;pill&rsquo; every<br />day, after the last hormone-containing tablet) of the &lsaquo;combined pill&rsaquo; and thus leave out the tablet-free<br />interval.<br />If the pack of the &lsaquo;previous pill&rsaquo; also contains tablets without active substances, you must not take<br />them.<br />If you are not sure what type of combined pill you have taken or which is the last hormone-containing<br />tablet, ask your doctor or pharmacist.<br />If you always used a vaginal ring or contraceptive patch correctly and consistently before switching, you<br />should start taking Microlut on the day of removal of the last vaginal ring or contraceptive patch of a<br />cycle pack and thus omit the hormone-free interval.<br />If you proceed as described earlier, however, continuous contraception is guaranteed.<br />R Switching from another minipill:<br />You can stop taking the previous minipill on any day you wish and start with Microlut on the very next<br />day.<br />If you take the tablets correctly, it is not necessary to take any additional contraceptive measures.<br />R Switching from an injection or implant:<br />Start taking Microlut at the time you would normally get the next injection or on the day the implant is<br />removed.<br />When switching from an implant or injectable product, an additional barrier method of contraception<br />must be used during the first seven days.<br />R After childbirth:<br />Women who are not breastfeeding can start taking the tablets 21 days after giving birth. An additional<br />barrier method must be used during the first seven days. If you have already had sexual intercourse,<br />pregnancy must be ruled out or you have to wait for your first menstrual bleeding before starting to<br />take Microlut.<br />R After a miscarriage or an abortion:<br />Please, talk to your doctor about when to start taking the tablets.<br />R Use in breastfeeding women:<br />(see &laquo;Pregnancy and breastfeeding&raquo;)<br />If you take more Microlut than you should<br />There have been no reports of serious deleterious effects from taking multiple Microlut tablets. If<br />multiple tablets are taken at once, nausea, vomiting and also slight vaginal bleeding may occur.<br />If you discover that a child has inadvertently taken several tablets, please see a doctor.<br />If you forget to take Microlut:<br />Even if only one tablet was taken late (i.e. if more than 27 hours have elapsed since the last tablet was<br />taken) or if one tablet was forgotten, contraceptive protection may be impaired.<br />The missed tablet should be taken as soon as possible, even if this means having to take two tablets at<br />the same time. Then, resume taking the tablets at your usual time. In addition, barrier methods have to<br />be used for the next seven days.<br />If you have had sexual intercourse in the last seven days, you could be pregnant. If this happens, please<br />see your doctor. The risk of becoming pregnant increases with the number of tablets you have forgotten.<br />If you suffer from vomiting and/or diarrhea<br />If you have to vomit within the first three to four hours of taking the tablet and/or have diarrhea, your<br />body may not have completely absorbed the active substance. This situation is comparable to missing<br />a tablet. If this happens, please follow the advice given in the previous section. An additional barrier<br />method of contraception has to be used for the following seven days. Take any replacement tablet(s)<br />from the end of the blister pack, so that you can still monitor your daily use according to the days of the<br />week on the blister pack.<br />If you stop taking Microlut<br />You can stop taking Microlut at any time. If you do not want to become pregnant, ask your doctor about<br />other reliable contraceptive methods.<br />If you have any further questions on the use of this product, refer to your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this pharmaceutical medicine can cause undesirable effects, although not everybody<br />gets them.<br />The following side effects have been reported following the use of Microlut:<br />Very common (more than 1 in 10 users can be affected):<br />Bleeding disturbances, such as spotting, intermenstrual bleeding or absence of menstrual bleeding<br />Common (1 in 10 users can be affected):<br />Depressed mood, libido decreased, libido increased, headaches, dizziness, nervousness, nausea, vomiting,<br />acne, breast pain, breast tension, painful menstruation, vaginal inflammation, prolonged menstrual<br />bleeding*, prolonged intermenstrual bleeding*<br />Uncommon (1 in 100 users can be affected):<br />Yellowish-brown pigmentation spots (Chloasma), fluid retention in tissue<br />Rare (1 in 1000 users can be affected):<br />Hypersensitivity reactions, contact lens intolerance, excess male pattern hair growth (Hirsutism), skin<br />conditions *, changes in vaginal discharge, weight increased, weight decreased.<br />(* generally applies to progesterone-only products)<br />As regards other severe undesirable effects, such as the formation of blood clots, liver tumors, breast<br />and cervical cancer, see &laquo;Warnings and precautions&raquo;.<br />Ectopic pregnancies are more likely to occur among users of the minipill than among users of combined<br />oral contraceptives (see also &laquo;The minipill and tubal (ectopic) pregnancy&raquo;). Persistent ovarian follicles<br />(functional ovarian cysts) may occur during the use of Microlut (see also &laquo;The minipill and persistent<br />ovarian cysts&raquo;).<br />Reporting side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any side effects not listed in<br />this leaflet. By reporting side effects, you can contribute to making more information about the safety of<br />this medicine available.<br />To report any side effect(s):<br />The National Pharmacovigilance Centre (NPC).<br />SFDA call center: 19999.<br />E - mail: npc.drug@sfda.gov.sa.<br />Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use after the expiry date stated on the folding carton and on the blister.<br />Storage conditions<br />Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Mircrolut contains:<br />The active substance is levonorgestrel<br />One coated tablet contains 0.03 mg levonorgestrel.<br />The other ingredient(s) are:<br />Lactose monohydrate, maize starch, polyvidone 25,000, talcum, magnesium stearate (Ph.Eur.), sucrose<br />(saccharose), polyvidone 90,000, macrogol 6,000, calcium carbonate, montanglycol wax</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Microlut looks like and contents of the pack
Microlut is available in packs of
1 blister pack with 35 coated tablets and
3 blister packs with each 35 coated tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufacturer:<br />Bayer AG<br />M&uuml;llerstrasse 178<br />13353 Berlin, Germany.<br />Marketing Authorisation Holder<br />Bayer AG<br />Kaiser-Wilhelm-Allee 1<br />51368 Leverkusen, Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This patient information leaflet was last revised in January 2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ميكرولوت مانع حمل هرموني ينتمي للمجموعة المسماه &laquo;الحبوب المصغرة&raquo;. على العكس من &laquo;الحبوب المركبة&raquo; (أقراص منع الحمل المركبة التى تؤخذ عن طريق الفم)، التي تحتوي عدد اثنين هرمون، استروجين و هرمون الجسم الأصفر (بروجيستوجين)، &laquo;الحبوب المصغرة&raquo; تحتوي فقط على هرمون واحد، و أيضاً في جرعة منخفضة.<br />ميكرولوت يستخدم لمنع الحمل.<br /><u>الأطفال:</u><br />لا يجب استخدام ميكرولوت قبل الحيض&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li><strong>يجب عدم تناول ميكرولوت</strong></li><li>إذا كان لديك فرط حساسية (أرجي) لليفونورجيسترل أو لأي مكونات أخرى لميكرولوت المذكورة في الجزء 6.</li><li>إذا كنت حامل أو يشتبه بحمل،</li><li>إذا كان هناك جلطة دموية في الأوردة، مثل في الساق (خثار وريدي عميق) أو في الرئة (انصمام رئوي) (راجع جزء &laquo;الحبة المصغرة و الخثار&raquo;)،</li><li>إذا كان هناك اعتلال و لو لمرة واحدة في أوعية الشرايين الدموية، مثل احتشاء قلبي، سكتة أو حالة فقر دم موضعي احتباسي قلبي (ذبحة صدرية) (راجع جزء &laquo;الحبة المصغرة و الخثار&raquo;)،</li><li>إذا كان لديك الداء السكري (السكري) و التغيرات الوعائية قد حدثت،</li><li>إذا كان لديك اضطراب شديد للكبد او حدث لك مرة في الماضي و قيم الكبد لم ترجع بعد الى طبيعتها،</li><li>إذا كان لديك الان او في الماضي ورم كبدي حميد او خبيث،</li><li>إذا كان لديك الآن أو في الماضي ورم خبيث يعتمد على الهرمونات الجنسية، مثل سرطان الثدي أو سرطان الأعضاء التناسلية، أو إذا كنت تشتبه أن لديك أي من هذه الأمراض.</li><li>في حالة حدوث نزف مهبلي، لم يتم توضيح سببه.</li></ul><p>إذا حدثت أي من الحالات المذكورة اعلاه خلال تناول ميكرولوت يجب التوقف عن تناول الدواء فوراً و زيارة طبيبك. في نفس الوقت يجب استخدام طريقة مختلفة غير هرمونية لمنع الحمل. راجع أيضاً جزء &laquo;التحذيرات و الاحتياطات &raquo;.<br /><strong>التحذيرات و الاحتياطات</strong><br />هذا الجزء يصف متى يجب التوقف الفورى عن تناول الحبة المصغرة أو متى يمكن أن تختل موثوقية الحبة المصغرة. في هذه الحالات يجب إما عدم حدوث اتصال جنسي أو استخدام طرق اخرى غير هرمونية لمنع الحمل، مثل العازل الطبي أو وسائل إعاقة اخرى. مع ذلك، لا تستخدم اساليب الروزنامة أو درجات الحرارة.<br />هذه الأساليب يمكن أن تفشل لأن تناول الحبة المصغرة يمكن أن تؤثر على التغييرات الشهرية فى درجة حرارة الجسم و في الأغشية المخاطية للرحم.<br />مثل كل أقراص منع الحمل التي تؤخذ عن طريق الفم ميكرولوت لا يمنح أي حماية من عدوى فيروس نقص المناعة البشري (العوز المناعي البشري) أو الامراض الاخرى المنقولة جنسياً.<br /><strong>الاختبار الطبي / الفحص الطبي الكامل</strong><br />قبل البدء أو استئناف تناول ميكرولوت يجب اخذ تاريخ الاصابات المرضية السابقة كاملا لك و لأقرب الأقارب؛ و يجب استبعاد احتمال وجود حمل. الاختبار الطبي (يشمل الحوض و الثدي) يجب ان يبين هذا التاريخ الطبي، موانع التناول و التحذيرات الخاصة بهذا المنتج الطبي. خلال فترة العلاج يوصى بفحوصات طبية منتظمة ملائمة للحالة الصحية الخاصة بك فى ما يخص تكرارها و طبيعتها. الفحوصات الطبية الكاملة، تشمل الثدي (تصوير الثدي إشعاعيا) يجب القيام به متوازباً مع الممارسة الوقائية الحالية و بما يناسب الحالة الصحية الخاصة بك.<br /><strong>المراقبة الحذرة بواسطة الطبيب تكون مطلوبة خصوصاً، إذا كان&nbsp;</strong></p><ul><li>لديك بوق فالوب واحد فقط ، حدث لك في الماضي التهاب لبوق فالوب مرة أو حدث حمل في البوق (انظر جزء &laquo;الحبة المصغرة و الحمل في البوق&raquo;)</li><li>إذا كنت تدخنين (انظر جزء &laquo;الحبة المصغرة و الخثار&raquo;)</li><li>لديك الداء السكري (السكري) (انظر جزء &laquo;الحبة المصغرة و الأمراض الاخرى&raquo;)</li><li>لديك زيادة في الوزن كبيرة (منسب كتلة الجسم أكثر من 30 كيلوغرام / متر مربع؛ انظر &laquo;الحبة المصغرة و الخثار&raquo;)</li><li>لديك انت او احد الأقارب المقربين انسداد وعائي في الأوردة (عند سن كان لا يزال صغيراً) (انظر جزء &laquo;الحبة المصغرة و الخثار&raquo;)</li><li>لديك ضغط دم مرتفع (انظر جزء &laquo;الحبة المصغرة و الامراض الآخرى&raquo;)</li><li>حدوث سرطان الثدي في الأقارب المقربين (انظر جزء &laquo;الحبة المصغرة و السرطان&raquo;)</li><li>لديك حالة كبد (انظر جزء &laquo;الحبة المصغرة و السرطان&raquo; و جزء &laquo;الحبة المصغرة و الأمراض الاخرى&raquo;)</li><li>كنت معرضة لظهور بقع صبغية (انظر جزء &laquo;الحبة المصغرة و الأمراض الاخرى&raquo;).</li></ul><p><strong>الحبة المصغرة و الخثار</strong><br />المصطلح تخثر ينطبق على تكون خثار (جلطة دموية) التي يمكن ان تسبب انسداد وعاء دموي. الخثار يحدث، في اماكن اخرى، في الأوردة العميقة أسفل الساق (خثار وريدي عميق). إذا حدث لمثل هذه الجلطة الدموية أن تنكسر و تتحرك بحرية، يمكن ان تتنقل في مجرى الدم الى شرايين الرئة و تسبب انسداد فى وعاء دموي (انصمام رئوي). الخثارات الوريدية العميقة نادرة. يمكن ان تحدث بصرف النظر عن سواء كنت تتناول &laquo;الحبة الصغيرة جداً&raquo; أو لا. يمكن أن تحدث أيضاً خلال الحمل.<br />الخثار لا يشفى دائماً بالكامل و في بعض الأحيان يخلف في نهايته إعاقات. الخثار يمكن كذلك ان يسبب الموت.<br />تشير فحوصات واسعة المجال بوجود علاقة بين تناول الحبوب المركبة و زيادة تكرار حدوث خثارات وريدية عميقة في الساق، و خثارات وريدية عميقة اخرى و الانصمامات الرئوية. تزداد إلى حد ما المخاطرة بحدوث خثار لدى السيدات اللاتي تتناولن هذه الأدوية أكثر من السيدات اللاتي لا تتناولن &laquo;الحبة المركبة&raquo; لمنع الحمل. اهمية هذه النتائج للحبوب الصغيرة جداً مثل الميكرولوت غير واضحة.<br />من المعروف أن مخاطرة المعاناة من انصمام خثاري وريدي تزداد مع العمر. إضافة لذلك المخاطرة تتزايد، إذا كان لديك زيادة شديدة في الوزن (منسب كتلة الجسم اكثر من 30 كيلو غرام لكل متر مربع) أو إذا كنت أو كان أحد أقاربك المقربين (أحد الأخوة أو الأقارب في عمر صغير نسبياً) كان لديه حالة انصمام خثاري وريدي.&nbsp;<br />مخاطرة الخثار الوريدي العميق في الساق يمكن أن تزداد وقتياً إذا كنت تخضعين لجراحة، لديك حالة تستلزم البقاء في السرير أو عدم القدرة على المشي (مثل إذا كانت الساق داخل الجبس). في هذه الحالة يجب اخطار طبيبك في وقت مناسب أنك تتناولين الحبة الصغيرة جداً. سوف ينصحك طبيبك بالتوقف عن تناول الحبة المصغرة لأسابيع عديدة قبل العملية الجراحية، عند بداية الراحة في السرير أو عدم الحركة. سوف يخبرك أيضاً متى يمكنك بداية تناول الحبة المصغرة مرة أخرى بعد ان تصبحين قادرة على المشي على قدميك مرة أخرى.<br />بطريقة مماثلة، يمكن أن تكون المخاطرة اعلى لحدوث جلطة دموية بعد الولادة.<br />يمكن أن يحدث ايضاً الخثار داخل شريان (خثار شرياني)، مثلاً داخل الشرايين التاجية للقلب أو الشرايين المغذية للدماغ، هكذا تؤدي إلى نوبة قلبية أو سكتة مخية. اظهرت دراسات المراقبة الإكلينيكية (السريرية) علامات قليلة جداً لأي صلة بين تناول الحبة المصغرة و زيادة المخاطرة للمعانة من احتشاء قلبي أو سكتة. عوامل المخاطرة المعروفة لحدوث مثل هذه الحالات هي العمر المتقدم، ارتفاع ضغط الدم و التدخين. مخاطرة المعاناة من سكتة يمكن أن تكون أعلى قليلاً لدى السيدات المصابات بارتفاع ضغط الدم اللآتي تتناولن الحبة الصغيرة جداً.<br />إذا كان لديك ضغط دم مرتفع عند تناول ميكرولوت يمكن أن تنصحين بالتوقف عن تناول الدواء و يجوز لك استخدام اسلوب آخر لمنع الحمل.<br />الأعراض الاتية يمكن أن تكون علامات لخثار وريدي او شرياني. إذا لاحظت أي من هذه الأعراض في نفسك، توقفي عن تناول الأقراص فوراً و يجب زيارة الطبيب في الحال.</p><ul><li>ألم غير معتاد أو تورم في الساق،</li><li>آلم و شعور ساحق في الصدر، ربما يشع للزراع الايسر،</li><li>حدوث مفاجئ لضيق فى التنفس،</li><li>نوبة سعال شديدة مفاجئة.</li><li>صداع غير معتاد شديد أو مستمر،</li><li>حدوث مفاجئ لفقدان جزئي أو كامل للرؤية،</li><li>رؤية مزدوجة،</li><li>كلام متداخل، مشاكل في التلفظ،</li><li>دوخة،</li><li>الإصابة بالهبوط، محتمل ارتباطه بنوبة صرع،</li><li>ضعف مفاجئ أو فقدان الحس (نمل) في نصف واحد أو جزء من الجسم،</li><li>حركات مضطربة (اضطرابات حركية)،</li><li>آلم شديد غير محتمل بالبطن،</li></ul><p><strong>الحبة المصغرة و السرطان&nbsp;</strong><br /><u>الثدي</u><br />يتواجد سرطان الثدي إلى حد ما أكثر في أحوال كثيرة في السيدات اللاتي تتناولن &laquo;الحبة المركبة&raquo; أكثر من السيدات في نفس العمر اللاتي لا تتناولن &laquo;الحبة المركبة&raquo; لمنع الحمل. غير معروف ما إذا كان ذلك بسبب &laquo;الحبة المركبة&raquo; يمكن أن يكون سبب الفرق الواقع. هو أن السيدات اللاتي تتناولن &laquo;الحبة المركبة&raquo; تخضعن لفحص أكثر انتظاما و اكثر شمولاً، لذلك يتم اكتشاف أي سرطان للثدي في وقت مبكر أكثر. الفرق يمكن أن يكون سببه مزيج من الاثنين (العوامل).<br />حيث أن سرطان الثدي يكون نادراً في السيدات في عمر أقل من 40، عدد الحالات الإضافية لحالات سرطان الثدي التي تم تشخيصها في اللاتى تتناولن &laquo;الحبة المركبة&raquo; حالياً أو سابقاً هو منخفض بالمقارنة بالمخاطرة الإجمالية.<br />بعد التوقف عن تناول &laquo;الحبة المركبة&raquo;، بيانات سرطان الثدي تقترب تدريجياً من بعضها البعض، و بعد 10 سنوات لا يمكن تبين أي اختلاف بين السيدات اللاتي تناولن &laquo;الحبة المركبة&raquo; سابقاً و السيدات الأخريات. في السيدات اللاتي تتناولن الحبة المصغرة من المحتمل أن تكون المخاطرة من نفس ترتيب الشدة كما هي في &laquo;الحبة المركبة&raquo;، على الرغم من أن موقف البيانات أقل حسماً للحبة الصغيرة جداً.&nbsp;<br />فى السيدات اللاتي تتناولن موانع حمل عن طريق الفم يكون ظاهراً أن مرحلة تطور أي سرطان للثدي قد تم تشخيصه إكلينيكياً (سريرياً) يكون أقل تقدماً عن السرطان الذي تم تشخيصه في السيدات اللاتي لا تتناولها.<br /><u>الكبد</u><br />في حالات نادرة تم اكتشاف أورام كبد حميدة و في حالات حتى أكثر ندرة تم اكتشاف اورام خبيثة، بين متناولي &laquo;الحبة المركبة&raquo;. في بعض الحالات المنفردة أدت هذه الأورام إلى نزيف داخلي مهدد للحياة. إذا عانيت فجأة من ألم شديد في البطن، يجب زيارة الطبيب فوراً.<br /><strong>اضطرابات نفسية</strong><br />بعض النساء اللاتي يستخدمن موانع الحمل الهرمونية بما في ذلك ميكرولوت أبلغن عن اعراض اكتئاب أو مزاج مكتئب. قد يكون الاكتئاب خطيرًا وقد يؤدي أحيانًا إلى أفكار انتحارية. إذا واجهتي تغيرات في المزاج أوأعراض اكتئاب، فاتصلي بطبيبك للحصول على مزيد من النصائح الطبية في أقرب وقت ممكن.&nbsp;<br /><strong>الحبة المصغرة و الأمراض الأخرى</strong><br />عامة الحبة المصغرة أظهرت أنه ليس لها تأثير على ضغط الدم في السيدات الأصحاء. لهذا أثناء تناول ميكرولوت إذا، حدث ارتفاع مستديم لضغط الدم، يجب عند ذلك التوقف عن تناوله.&nbsp;<br />يجب التوقف عن تناول ميكرولوت إذا حدث حك يشمل كل الجسم (حكة مسببة من ركود الصفراء) أو احتباس الصفراء (يرقان متعلق بركود الصفراء). مطلوب حذر خاص، إذا حدثت هذه الحالات من قبل في حمل سابق أو عند تناول هرمونات.<br />إذا كان لديك الداء السكري (السكري) الجرعة المطلوبة من الدواء المتناول لعلاج الداء السكري يمكن أن تتغير عندما يتم تناول ميكرولوت. مرضى الداء السكري و السيدات اللاتي اصيبن بالداء السكري في حمل سابق يجب لذلك مراقبتهن بعناية، خاصة خلال المرحلة الأولى من التناول.<br />بقع تصبغ بنية مصفرة للجلد (كلف) يمكن أن تحدث أحياناً، خاصة لدى السيدات اللاتي عانين من ذلك أثناء الحمل. السيدات اللاتي لديهن قبول لهذا يجب لذلك أن لا يعرضن أنفسهن مباشرة لضوء الشمس أو للضوء الفوق بنفسجي (مثل مشمسة) عند تناولهن ميكرولوت.<br /><strong>الحبة المصغرة و الحمل الأنبوبي (في البوق)</strong><br />في هذه الحالات الاستثنائية عندما تصبح السيدة حامل عند تناولها الحبة الصغيرة جداً، يوجد احتمال أكبر عن وجود حمل في البوق لدى السيدات اللاتي تتناول الحبة المصغرة عن السيدات اللاتي تتناول &laquo;الحبة المركبة&raquo;.<br />لهذا السبب السيدات اللاتي كان لديهن حمل في البوق في الماضي، و يعانين أو عندما يبدأن بالمعاناة من التهاب المبيض أو لديهن بوق فالوبي واحد، يجب أن يتناولن فقط ميكرولوت بعد تقييم الطبيب بعناية للمخاطر و الفوائد لهذه الحالة الخاصة.<br />إذا حدث آلم لم يتم تفسيره في الجزء الأسفل من البطن مع دورة شهرية غير منتظمة (عدم النزف أو استطالة الوقت بدون نزف يتبعه نزف مستمر)، يؤخذ فى الاعتبار احتمال وجود حمل في البوق. في هذه الحالة يجب زيارة الطبيب فوراً.<br /><strong>الحبة المصغرة و التكيسات الدائمة للمبيض</strong><br />خلال تناول الحبة المصغرة يمكن حدوث حويصلات دائمة للمبيض (عادة تسمى أيضاً تكيسات وظيفية للمبيض). معظم هذه الحوصلات لا تسبب شكاوي، لكن بعض منها يمكن أن يؤدي للألم في أسفل البطن أو خلال الاتصال الجنسي (جماع مؤلم). في معظم الحالات هذه الحوصلات المتضخمة تختفي من تلقاء نفسها خلال شهرين أو ثلاثة من المراقبة.<br /><strong>في الحالات الآتية يجب عليك زيارة الطبيب في أسرع وقت ممكن.</strong></p><ul><li>تغييرات لحالتك الصحية، مثل حدوث حالات موصوفة في أي مكان في تعليمات الاستخدام هذه (انظر جزء &laquo;يجب عدم تناول ميكرولوت&raquo; و جزء &laquo;التحذيرات و الاحتياطات &raquo;؛ يؤخذ في الاعتبار ايضاً أي حالات تحدث لأحد الأقارب المقربين).</li><li>كتل في الثدي،</li><li>استمرار أو زيادة النزف الغير منتظم.</li><li>إذا نسيت تناول الأقراص أو تناولتها متأخراً و حدث اتصال جنسي.</li><li>إذا لم يحدث النزف الشهري لمدة ستة اسابيع على التوالي (فقط ابدئي شريط جديد من العبوة عندما تتأكدين من عدم وجود حمل)،&nbsp;</li><li>إذا كان لديك آلم غير معروف تفسيره في اسفل البطن شامل معه نمط نزف غير منتظم (النزف الشهري لا يحدث أو إذا فشل النزف في الحدوث و بعد ذلك يحدث نزف غير منتظم، انظر جزء &laquo;الحبة المصغرة و الحمل في البوق&raquo;).</li><li>إذا لاحظت علامات ممكنة لخثارات (انظر جزء &laquo;الحبة المصغرة و الخثار&raquo;).</li></ul><p><strong>ضعف الفاعلية</strong><br />يمكن أن تضعف فاعلية الميكرولوت، إذا</p><ul><li>تم نسيان قرص أو عدة أقراص أو تم تناولهم متأخرين (انظر جزء &laquo;إذا نسيت تناول ميكرولوت &raquo;)،</li><li>حدوث قيء أو اسهال شديد (انظر جزء &laquo;ما الذي يجب فعله في حالة القيء و/أو الاسهال&raquo;)،</li><li>تناول أدوية اخرى معينة في نفس الوقت (انظر جزء &laquo;تناول ميكرولوت، مع أدوية اخرى&raquo;).</li></ul><p>إذا تم تناول ميكرولوت مع مستحضرات تحتوي على عشب سنت جون في نفس الوقت، نوصي باستخدام اسلوب اعاقة اضافي لمنع الحمل (انظر جزء &laquo;تناول ميكرولوت مع أدوية اخرى&raquo;).<br /><strong>اضطرابات الدورة</strong><br /><u>النزف الشهري</u><br />في معظم الحالات عندما يتم تناول الحبة المصغرة يكون حدوث النزف عند الفترات الطبيعية، بمدة و شدة طبيعية. و مع ذلك، تم ملاحظة فترات اقصر أو اطول بين فترات النزف.<br />هذه التغيرات تحدث أكثر في الشهور الأولى من التناول. بعد ذلك اثناء التناول نمط النزف يثبط و في معظم الحالات ينشىء نمط شخصي. يجب عادة تسجيل النزف في روزنامة.<br /><u>ما العمل في حالة النزف بين الحيضين</u><br />يمكن حدوث نزف بين الحيضين بشدة مختلفة، خاصة في الشهور الأولى. من وجهة النظر الطبية هذا لا يسبب التوقف عن تناول الميكرولوت. يجب عليك، مع ذلك، اخطار طبيبك لإستبعاد أي سبب عضوي لمثل هذا النزف.<br /><u>لا يحدث نزف انسحابي</u><br />يمكن أن يحدث فشل وجود نزف شهري، لكن في معظم الأحوال هذا ينطبق فقط على دورة أو دورتين. في حالات نادرة الفشل في النزف يمكن أن يستمر لفترات أطول.<br />إذا فشل النزف أن يحدث مرة أخرى خلال فترة ستة اسابيع من آخر نزف، يجب زيارة الطبيب لكي يستبعد وجود حمل قبل تناول مزيد من الأقراص.<br /><strong>معلومات إضافية لمجموعات معينة من المرضى</strong><br /><u>الأطفال والمراهقين</u><br />ميكرولوت ليس مناسب للاستخدام قبل الدورة الشهرية الأولى (الحيض).<br /><u>النساء كبار السن</u><br />ميكرولوت ليس مناسب للاستخدام بعد سن اليأس (انقطاع الدورة).<br /><u>النساء اللاتي تعاني من ضعف وظائف الكبد</u><br />لا تأخذي ميكرولوت إذا كنت تعاني من اضطرابات الكبد الشديدة. انظري أيضا أقسام &laquo;لا تأخذي ميكرولوت&raquo; و &laquo;التحذيرات والاحتياطات&raquo;.<br /><strong>تناول ميكرولوت مع أدوية اخرى</strong><br />رجاء تبليغ طبيبك او الصيدلي إذا كنت حالياً أو حديثاً كنت تتناولين أدوية اخرى او تنوين استعمال أدوية أخرى، حتى إذا كانت هذه الأدوية تصرف بدون تذكرة طبية. و أيضاً أخطري أي طبيب أو طبيب الأسنان الذي يصف لك أدوية أخرى (أو الصيدلي) أنك تتناولين ميكرولوت. يمكنهم بعد ذلك معرفة ما إذا كنت بحاجة إلى استخدام أساليب إضافية لمنع الحمل، وإذا كان الجواب نعم، فإلى متى.<br />رجاء ملاحظة أن هذا يمكن أيضاً أن ينطبق على أدوية تم تناولها حديثاً.<br />بعض الأدوية:</p><ul><li>قد يكون لها تأثير على مستويات الميكرولوت في الدم</li><li>قد تقلل فعالية الحبة المصغرة (ميكرولوت) في منع الحمل،</li><li>قد تتسبب في حدوث نزيف غير متوقع.</li></ul><p>من بينها الآتي:</p><ul><li>الأدوية التي تُستخدم لعلاج:</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - الصرع (مثل بريميدون، فينيتوين، باربيتورات، كاربامازيبين، أوكسكاربازيبين، توبيراميت، فيلبامات)<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - السل (مثل ريفامبيسين)<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - إصابات فيروس نقص المناعة البشرية (الإيدز) والعدوى بفيروسC (التهاب الكبد الوبائي) (المسماة مثبطات الأنزيم البروتيني و مثبطات إنزيم النسخ العكسي الغير&nbsp;نوكليوزيد)<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - الالتهابات الفطرية (مثل غريزيوفولفين، أدوية أزول المضادة للفطريات، على سبيل المثال، فلوكونازول، إتراكونازول، كيتوكونازول، فوريكونازول)<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - العدوى البكتيرية (المضادات الحيوية ماكرولايد، على سبيل المثال، كلاريثروميسين، الاريثروميسين)<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - بعض أمراض القلب، ارتفاع ضغط الدم (حاصرات قنوات الكالسيوم، مثل، فيراباميل، ديلتيازيم)</p><ul><li>العلاج العشبي بنبتة سانت جون (تستخدم أساسا لعلاج الاكتئاب)</li><li>عصير الجريب فروت</li></ul><p>إذا كنت تحتاجين تناول مثل هذه الأدوية لمدد أطول، رجاء اخذ نصيحة طبيبك المعالج. اعتماداً على الحالة التي يمكن أن تكوني فيها ربّما يجب استخدام اسلوب مختلف لمنع الحمل غير هرموني.<br />قد تؤثر الحبة المصغرة (ميكرولوت) على تأثير الأدوية الأخرى. وبناء على ذلك، قد تزيد تركيزات البلازما والأنسجة (مثل السيكلوسبورين، وهو دواء يستخدم لمنع رفض زرع الأعضاء).<br />ملاحظة: يجب مراجعة ارشادات الاستخدام الخاصة بالأدوية التي تتناول في نفس الوقت لاحتمال أي تفاعلات.<br /><strong>الاختبارات المعملية</strong><br />أخبري طبيبك أو موظفي المختبر بأنك تتناولين ميكرولوت إذا كان عليك إجراء فحص دم أو اختبارات مخبرية أخرى، إذ قد يؤدي استخدامه إلى التأثير على نتائج بعض الاختبارات.<br /><strong>الحمل و الرضاعة الطبيعية</strong><br />إذا كنت حاملا أو ترضعين طبيعيا أو تعتقدين أنك قد تكونين حاملا، يجب عليك عدم تناول ميكرولوت.<br /><u>الحمل</u><br />إذا حدث حمل أثناء تناول ميكرولوت، توقفي فوراً عن تناوله و استشيري الطبيب.<br />التأثيرات الهرمونية الغير مرغوبة على نمو الأعضاء البولية والتناسلية لا يمكن استبعادها بالكامل، لكن معظم الدراسات العلمية التي تمت حتى اليوم لم تشير لأي زيادة للمخاطرة بحدوث تشوهات في الجنين لدي الأمهات اللاتي تناولن موانع حمل قبل الحمل، و لا يوجد أي إشارة لتأثير مسبب لتشوهات ناتج من تناول غير مقصود لهرمون الجسم الأصفر بجرعات مثل الموجودة في الميكرولوت أثناء الحمل.<br /><u>الرضاعة الطبيعية</u><br />الحبة المصغرة تعتبر وسيلة الاختيار الثانية بعد أساليب منع الحمل الغير هرمونية.<br />إذا بدأ تناول الحبة المصغرة بعد ستة اسابيع من الولادة، فى تلك النقطة تراءى أنه لا يوجد تأثيرات مؤذية على نمو و تكوين الطفل الراضع من الثدي. لا يوجد دليل يقترح أن الحبة المصغرة تضعف جودة و كمية لبن الثدي، على الرغم من أن كميات صغيرة من المادة الفعالة تفرز في اللبن.<br /><u>القدرة على القيادة و تشغيل الماكينات</u><br />لا يوجد احتياج لتدابير خاصة.<br /><u>يحتوي ميكرولوت على سكر (سكروز) و سكر اللبن (لكتوز)</u><br />رجاء استشارة الطبيب قبل تناول ميكرولوت، إذا كنت تعلمين أن لديك حساسية (ارجي) لبعض أنواع السكر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب دائماً تناول ميكرولوت حسب تعليمات الطبيب تماماً. رجاء طلب ذلك من الطبيب أو الصيدلي إذا كنت غير متأكدة تماماً.<br /><strong>طريقة التناول</strong><br />هذا المنتج الطبي يجب تناوله عن طريق الفم.<br />رجاء تناول الأقراص صحيحة (سليمة &ndash; بكاملها &ndash; غير مقسمة &ndash; غير مجزئة) مع كمية سائل كافية (يفضل كوب من الماء).<br /><strong>الجرعة الاعتيادية هي كما يلي، إلا إذا وصف الطبيب خلاف ذلك:</strong><br />قرص واحد يومياً.<br />يتم تناول ميكرولوت باستمرار يعني ذلك بدون التوقف عن التناول.&nbsp;<br />هذا يعني في حالة انك تناولت كل الأقراص من شريط واحد فى العبوة تبدئين بعد ذلك مباشرة بتناول الأقراص من شريط العبوة التالي.<br />يجب تناول ميكرولوت عند نفس الوقت كل يوم، قريب بقدر الإمكان من التوقيت الدقيق لليوم و باستمرار بدون أي انقطاع بغير قرص، وبغض النظر عما إذا حدث اي نزيف (نزيف شهري أو حتى نزيف بين الحيضين).<br />الفترة الفاصلة بين الأقراص المتتالية يجب أن تكون بقدر الأمكان قريبة لـ 24 ساعة. هذا الوقت يجب أن لا يتم تجاوزه بأكثر من ثلاثة ساعات في كل الحالات لتجنب تعرض التأثير المانع للحمل للخطر. يمكن فقط ضمان اقصى موثوقية للميكرولوت إذا تم الحفاظ على الوقت بين تناول الأقراص قريب بقدر الإمكان لـ 24 ساعة.<br /><strong>متى يجب البدء بتناول الأقراص من أول شريط للعبوة؟</strong></p><ul><li><strong>إذا كنت لم تتناولين أي &laquo;حبة&raquo; لمنع الحمل في الشهر الماضي.</strong></li></ul><p>ابدئي تناول ميكرولوت في أول يوم للدورة، ذلك يعني أول يوم من النزف في الدورة الشهرية.<br />ينزع القرص الأول من حفرة الشريط الموسومة بعلامة يوم الاسبوع المختصر لبداية تناول القرص (مثل &ldquo;Mo&rdquo; ليوم الاثنين). استمر في تناول الأقراص مع اتجاه الأسهم حتى تمام استخدام كل الـ 35 قرص في شريط العبوة.<br />ثم ابدئي في تناول الأقراص من الشريط التالي في اليوم التالي لذلك.<br />إذا بدئت تناول ميكرولوت بعد اليوم الأول للدورة الشهرية، يجب استخدام وسيلة إعاقة لمنع الحمل إضافية في السبعة أيام الأولى. إذا اتبعت ما تم وصفه سابقاً، فإن منع الحمل يكون مضمون منذ بداية تناول القرص.</p><ul><li><strong>التحول من &laquo;الحبة المركبة&raquo;:</strong></li></ul><p>ابدئي تناول ميكرولوت في نفس اليوم الذى تناولت فيه آخر قرص من &laquo;الحبة المركبة&raquo; المحتوي على المواد الفعالة.<br />إذا كانت العبوة السابقة من &laquo;الحبة المركبة&raquo; أيضاً تحتوي أقراص بدون مواد فعالة، يجب عدم تناولهم.<br />إذا كنت لا تعلمين أيّهما يكون آخر قرص المحتوي على مادة فعالة، اسألي طبيبك أو الصيدلي.<br />إذا اتبعت ما تم وصفه سابقاً، فإن منع الحمل المتواصل يكون مضمون.</p><ul><li><strong>التحول من حبة مصغرة اخرى:</strong></li></ul><p>يمكن أن تتوقفي عن تناول الحبة المصغرة السابقة في أي يوم محدد و تبدئين تناول ميكرولوت من اليوم التالي مباشرة.<br />إذا تناولت الأقراص كما هو مفروض لا يستدعي ذلك أخذ أي تدابير مانعة للحمل اضافية.</p><ul><li><strong>التحول من الحقن أو الغرسة:</strong></li></ul><p>ابدئي تناول ميكرولوت في توقيت الحقنة التالية التي كان يجب أن تؤخذ، أو في يوم نزع الغرسة.<br />عندما يتم التحول من الغرسة أو الحقنة يجب استخدام اسلوب إعاقة منع الحمل إضافي خلال السبعة ايام الأولى.</p><ul><li><strong>بعد الولادة:</strong></li></ul><p>السيدة التي لا ترضع من الثدي يمكنها أن تبدأ بتناول الأقراص 21 يوم بعد الولادة.<br />خلال السبعة أيام الأولى يجب استخدام اسلوب إعاقة إضافي. إذا تمت علاقة جنسية قبل ذلك، يجب التأكد من عدم وجود حمل قبل البدء في تناول ميكرولوت، أو يجب انتظار نزف أول دورة شهرية.</p><ul><li><strong>بعد اتمام الإجهاض أو إنهاء الحمل مباشرة:</strong></li></ul><p>رجاء اسألي طبيبك متى يجب البدء.</p><ul><li><strong>الاستخدام في السيدات اللائي ترضعن من الثدي:</strong></li></ul><p>انظر جزء &laquo;الحمل و الرضاعة الطبيعية&raquo;<br />&nbsp;</p><p><strong>إذا تناولت ميكرولوت أكثر مما يجب:</strong><br />لا توجد تقارير عن تأثيرات ضارة خطيرة على الصحة من تناول عدة اقراص ميكرولوت مرة واحدة. إذا تم تناول عدة اقراص في نفس الوقت يمكن ان يحدث غثيان، قيء و ايضاً نزف مهبلي طفيف.<br />إذا اكتشفت أن طفل قد تناول عدة اقراص بدون قصد، رجاء زيارة الطبيب.<br /><strong>إذا تم نسيان تناول ميكرولوت:</strong><br />حتى إذا تم تأخير تناول قرص واحد فقط (ذلك يعني إذا تم مرور اكثر من 27 ساعة على آخر قرص تم تناوله) أو إذا تم نسيان قرص واحد، يمكن ان تضعف حماية منع الحمل.<br />يجب تناول القرص المنسي في اسرع وقط ممكن، حتى إذا كان يعني ذلك تناول قرصين في نفس الوقت. بعد ذلك، يستأنف تناول القرص عند الوقت الطبيعي من اليوم. اضافة لذلك، يجب استخدام اسلوب إعاقة للسبعة أيام التالية.<br />إذا تم القيام باتصال جنسي خلال السبعة ايام السابقة، فمن المحتمل انه قد نتج حمل. في هذه الحالة اخطر طبيبك. مخاطرة حدوث حمل تزداد مع عدد الأقراص المنسية.<br /><strong>إذا كان لديك قيء أو اسهال</strong><br />إذا كان لديك قيء خلال الثلاثة أو الاربعة ساعات الأولى من تناول القرص و / او كان لديك اسهال، المادة الفعالة في القرص من المحتمل أنها لم تمتص كاملة بواسطة الجسم. الحالة تكون شبيهة لنسيان تناول قرص. في هذه الحالة اتبعي النصيحة المعطاة في الجزء السابق. يجب استخدام اسلوب إعاقة إضافي لمنع الحمل خلال السبعة أيام التالية. اي استبدال لقرص (للأقراص) يجب أن يؤخذ من نهاية شريط العبوة لكى يحتفظ الفرد بنظرة عامة للتناول اليومي للأقراص من ايام الاسبوع الظاهرة على شريط العبوة.<br /><strong>إذا توقفت عن تناول ميكرولوت :</strong><br />يمكن التوقف عن تناول ميكرولوت في أي وقت. إذا كنت لا تريدين ان تصبحي حامل، اسألي طبيبك عن اساليب اخرى موثوقة لمنع الحمل.<br />إذا كان لديك أي اسئلة اضافية عن تناول هذا الدواء، اسألي طبيبك او الصيدلي.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل أي دواء، يمكن لميكرولوت أن يكون له آثار جانبية، و لكن ليس من الضرورة مع كل مستخدم.<br />تم التبليغ عن الآثار الجانبية الآتية بعد تناول ميكرولوت:<br /><strong>شائع جدا (قد تصيب أكثر من واحد من كل 10 مستخدم)</strong><br />اضطرابات نزفية مثل التبقع، النزيف بين دورات الحيض أو غياب النزف الشهري<br /><strong>شائع (قد تصيب واحد من كل 10 مستخدم)</strong><br />مزاج مكتئب، تغير في الشبق (الشهوة الجنسية)، صداع، دوخة، عصبية، غثيان، قيء، حب الشباب، آلم الثدي، توتر الثدي، دورة شهرية مؤلمة، التهاب مهبلي، استطالة نزف الدورة الشهرية*، مزيد من استطالة النزف بين الحيضين*<br /><strong>غير شائع: (قد تصيب واحد من كل 100 مستخدم)</strong><br />بقع تصبغ للجلد بنية &ndash; مصفرة (كلف)، احتباس السوائل في الانسجة<br /><strong>نادر: (قد تصيب واحد من كل 1000 مستخدم)</strong><br />تفاعلات فرط الحساسية، تحمل ضعيف (قليل) للعدسات اللاصقة، زيادة نمو الشعر ذكري النمط (زبب)، حالات جلدية، تغييرات في الإفرازات المهبلية،<br />تغيير وزن الجسم<br />* ينطبق عامة على التحضيرات التي تحتوي فقط على هرمون واحد للجسم الأصفر<br />انظر جزء &laquo;التحذيرات و الاحتياطات&raquo; للآثار الجانبية العسيرة الاخرى مثل تجلط الدم، أورام الكبد، سرطان الثدي او سرطان عنق الرحم.<br />الحمل في البوق يحدث اكثر تكرار في مستخدمي الحبة المصغرة أكثر من مستخدمي موانع الحمل التي تؤخذ بالفم المركبة (راجع جزء &laquo;الحبة المصغرة و الحمل في البوق&raquo;). خلال تناول ميكرولوت يمكن أن يحدث حويصلات مستمرة للمبيض (تكيسات وظيفية للمبيض) (راجع جزء &laquo;الحبة المصغرة و الحويصلات المستمرة للمبيض&raquo;).<br /><strong>التبليغ عن الآثار الجانبية</strong><br />إذا تم إصابتك بأي من الآثار الجانبية، يجب التبليغ عنها للطبيب أو الصيدلي. هذا يشمل أي آثار جانبية محتملة، غير مذكورة في هذه النشرة. يمكن أن تساعدي على توفير مزيد من المعلومات حول سلامة هذا الدواء عن طريق التبليغ عن الآثار الجانبية.<br /><strong>للإبلاغ عن أي أعراض جانبية</strong><br />المركز الوطني للتيقظ الدوائي<br />فاكس: 7662 &ndash; 205 &ndash; 11 &ndash; 966 +<br />مركز اتصال الهيئة العامة للغذاء والدواء: 19999<br />البريد الالكتروني: npc.drug@sfda.gov.sa<br />الموقع الالكتروني: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن متناول أيدي و نظر الأطفال.<br />يجب عدم تناول الدواء بعد تاريخ انتهاء المفعول المذكور على العلبة الكرتونية و أسفل شريط العبوة .<br /><strong>شروط التخزين</strong><br />يحفظ في درجة حرارة أقل من 30 درجة مئوية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u>المادة الفعالة</u> هي ليفونورجيسترل.<br />يحتوي كل قرص مغلف على 0.03 ميليغرام ليفونورجيسترل.<br /><u>المكونات الأخرى</u> هي:<br />لاكتوز أحادي الهيدرات، نشأ الذرة، بوليفيدون 25.000، تلك، ستيارات الماغنسيوم (دستور الأدوية الأوروبية)، سكروز، بوليفيدون 90.000، ماكروغول 6.000، كربونات الكالسيوم، شمع مونتانغليكول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتوفر ميكرولوت في عبوات تحتوي على عبوة شريط واحد يحتوي 35 قرص مغلف، و عبوة ثلاثة شرائط يحتوي كل منها 35 قرص مغلف. قد لا تتوافر جميع العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>المصنع:</strong><br />باير ايه جي<br />178 موللرشتراس<br />13353 برلين، ألمانيا.<br /><strong>حامل ترخيص التسويق:</strong><br />باير ايه جي<br />قيصر - ويلهلم - آلي 1،<br />51373 ليفركوزن، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر 2018.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Microlut 30 microgram coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levonorgestrel

One coated tablet contains: 30 µg Levonorgestrel         

Other constituents with known effect: 33 mg lactose monohydrate and 19.6 mg sucrose (see section 4.4).

See section 6.1 for a full list of all the other constituents.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Coated tablet

The tablets are white, biconvex, and round.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt">Contraception for women</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:.5in; margin-right:0in"><em>Posology</em></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:49.6pt">One tablet of Microlut daily without tablet-free breaks</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:.5in; margin-right:0in"><em>Method of administration</em></p><p style="margin-left:49.6pt">&nbsp;</p><p style="margin-left:49.6pt">The first tablet is removed from a blister pack well marked with the abbreviated day of the week for the start of tablet-taking. The tablets are taken continually for 35 days in the direction of the arrows, irrespective of whether bleeding occurs.<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p style="margin-left:49.65pt">The day after the tablets from one blister pack have been used up, the first tablet from a new blister pack is taken.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">The tablets must be taken at about the same time every day with a sufficient amount of liquid. The interval between two consecutive tablets should be as close as possible to 24&nbsp;hours. To avoid jeopardizing the contraceptive effect this time must not be exceeded by more than three hours at all events. The maximum reliability of Microlut can only be guaranteed if the time between tablet-taking is kept as close as possible to 24&nbsp;hours.</p><p style="margin-left:49.65pt; margin-right:0in"><em>&nbsp;</em></p><p style="margin-left:.5in; margin-right:0in"><em>Starting to take Microlut</em></p><p style="margin-left:49.65pt; margin-right:0in"><em>&nbsp;</em></p><p style="margin-left:63.8pt; margin-right:0in; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->When not preceded by the taking of hormonal contraceptives (in the previous month)<br /><br />Tablet-taking is to start on the first day of the natural cycle (i.e. 1<sup>st</sup> day of menstruation). If the taking of Microlut starts later, an additional barrier method of contraception is to be used in the first seven days.<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p style="margin-left:63.8pt; margin-right:0in; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Switching from a combined oral contraceptive (COC), a vaginal ring or a transdermal patch<br /><br />If the user used the previous product correctly and consistently, she should start taking Microlut the day immediately after taking the last tablet of the previous hormone-free preparation and thus omit the hormone-free interval of this COC. The user must be instructed that if the contraceptive used previously also contained hormone-free tablets, such latter tablets are not to be taken. If a vaginal ring or transdermal patch was used correctly and consistently prior to the switch, the user should start taking Microlut on the day of removal of the last vaginal ring or transdermal patch of a cycle pack and thus omit the hormone-free interval. This approach ensures uninterrupted contraception.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:63.8pt; margin-right:0in; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Switching from another progestogen-only pill (POP, injectable product, implant)<br /><br />If another oral progestogen-only pill (POP) was taken previously, the switchover can take place on any day without a tablet-free break.. If {the tablets} were taken correctly, no additional contraceptives measures need be applied.<br /><br />When switching from an implant, the taking of Microlut must start on the day of removal, and when switching from an injectable product tablet-taking must start at the time the next injection would have been due.<br />When switching from an implant or injectable product an additional barrier method must be employed during the first seven days.<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p style="margin-left:63.8pt; margin-right:0in; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->After a first-trimester termination<br /><br />The taking {of Microlut} can start immediately. During the first seven days an additional barrier method must be used.</p><p style="margin-left:63.8pt; margin-right:0in">&nbsp;</p><p style="margin-left:63.8pt; margin-right:0in; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->After a birth or abortion in the second trimester of pregnancy<br /><br />Women who are not breast-feeding can start taking Microlut<sup> </sup>21 days after a birth or second-trimester miscarriage. During the first seven days an additional barrier method must be used. If sexual intercourse has already taken place, pregnancy must be ruled out before you start taking Microlut, or the first menstrual bleeding must be waited for.<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p style="margin-left:63.8pt; margin-right:0in; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->See section 4.6 &quot;Pregnancy and lactation&rdquo; for use in the case of breastfeeding women.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What to do when tablets were forgotten</em></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Even if only one tablet was taken late (i.e. if more than 27&nbsp;hours have elapsed since the last tablet was taken) or if one tablet was forgotten, contraceptive protection may be impaired.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">The missed tablet should be taken as soon as possible, even if this means having to take two tablets at the same time. After this, tablet-taking is resumed at the normal time of day. In addition, a barrier method is to be used for the next seven days.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">If sexual intercourse has taken place in the previous seven days, the possibility that pregnancy may have occurred should be considered. The risk of pregnancy occurring increases with the number of tablets missed.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What to do in case of vomiting or severe diarrhea</em></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">If vomiting or diarrhea occurs within the first three to four hours of tablet-taking, the active substance may possibly not have been completely absorbed by the intestines. In such a case the same advice as given above for a missed tablet shall apply, i.e. an additional barrier method must be used on the following seven days.</p><p style="margin-left:49.65pt; margin-right:0in">Any replacement tablet(s) should be taken from the end of the current pack so that one retains an overview of daily tablet-taking from the days of the week shown on the blister pack.</p><p style="margin-left:49.65pt; margin-right:0in"><em>&nbsp;</em></p><p style="margin-left:0in; margin-right:0in; text-indent:35.45pt"><em>Additional information for particular patient groups</em></p><p style="margin-left:0in; margin-right:0in; text-indent:35.45pt"><em>Children and adolescents</em></p><p style="margin-left:49.65pt; margin-right:0in">Before the menarche there is no relevant indication for Microlut.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in"><em>Elderly patients</em></p><p style="margin-left:49.65pt; margin-right:0in">Not applicable. There is no indication for Microlut after the menopause.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in"><em>Patients with impaired hepatic function</em></p><p style="margin-left:49.65pt; margin-right:0in">Microlut is contraindicated in women with severe hepatic disorders (see section&nbsp;4.3).</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in"><em>Patients with impaired renal function</em></p><p style="margin-left:49.65pt; margin-right:0in">Microlut has not been specifically investigated in patients with impaired renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Microlut must not be used if any of the following disorders/risk factors apply. If any of these disorders/risk factors occur for the first time while Microlut is being taken, the drug must be stopped immediately.

Microlut must not be used in case of:

	hypersensitivity to the active substance or any other constituents listed in section 6.1,
	known or suspected pregnancy,
	present venous thromboembolic disorders (deep vein thrombosis, pulmonary embolism),
	past or present arterial and cardiovascular disorders (e.g. cerebrovascular attack, myocardial infarction) or prodromal signs (e.g. angina pectoris and transitory ischemic attack),
	diabetes mellitus with vascular changes,
	past or present severe hepatic disorders as long as liver function values have not returned to normal,
	past or present hepatic tumors (benign or malignant),
	known or suspected malignant disorders of the genital organs or breast, provided these are susceptible to sex hormone influence,
	unclarified vaginal hemorrhage.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt; margin-right:0in">Patients with the rare congenital fructose intolerance, congenital galactose intolerance, glucose/galactose malabsorption, sucrase-isomaltase deficiency or lactase deficiency should not take Microlut.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<u>Medical examination/consultation</u></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Before Microlut is prescribed for the first time or again at a later date a full medical history must be collected (including family history), and a physical checkup must be conducted based on the contraindications (see&nbsp;section 4.3) and warnings (see&nbsp;section 4.4). Blood pressure should be measured and a pregnancy be ruled out.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">The user must also be advised to read the directions for use carefully and to follow them. The frequency and extent of checkups should be based on the applicable established practice guidelines and be adapted to the individual woman.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">The user should be advised that the taking of oral contraceptives does not protect against HIV infections (AIDS) and other sexually transmitted diseases.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Warnings</u></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">If any of the disorders/risk factors listed below is present, the benefit of Microlut should be weighed against the possible risks for the individual woman and should be discussed with her before she decides to start taking it. In case any of these disorders is exacerbated or occurs for the first time, or if risk factors arise, the woman must consult her physician. The latter will decide whether Microlut must be discontinued or not.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Vascular disorders</em></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Epidemiological studies provide scarcely any evidence for a correlation between the use of hormonal contraceptives that contain a progestogen only and an enhanced risk of sustaining myocardial infarction and cerebral thromboembolism. The risk of sustaining cardiovascular and cerebral events is more closely associated with increasing age, high blood pressure and smoking. The risk of suffering a stroke might be slightly higher in women with high blood pressure taking oral contraceptives with a progestogen only.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">The risk for venous thromboembolisms may be slightly, but not statistically significantly, increased.</p><p style="margin-left:49.65pt; margin-right:0in">The taking of Microlut should be discontinued if a thrombosis occurs. One should also consider stopping Microlut in the case of immobilization due to surgery or illness. Women with a history of thromboembolic disorders should be advised of a possible reoccurrence.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">The generally recognized risk factors for venous thromboembolism (VTE) include</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:67.65pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->a personal or family history of the occurrence of VTE (in a sibling or parent at a relatively young age),</p><p style="margin-left:67.65pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->advancing age,</p><p style="margin-left:67.65pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->obesity (body mass index above 30 kg/m&sup2;),</p><p style="margin-left:67.65pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->prolonged immobilization, major surgery, any leg surgery or extensive injuries. In these situations it is advisable to stop taking the POP (in the case of elective surgery at least four weeks in advance) and to restart not earlier than two weeks after complete mobility has been restored. Thrombosis prophylaxis should be considered if the POP has not been stopped in time.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">The enhanced risk of thromboembolism in the puerperium must also be taken into account.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Taking must be discontinued immediately any symptoms of an arterial or venous thrombosis occur or if this is suspected.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Symptoms of venous or arterial thrombosis may be:</p><p style="margin-left:63.8pt; margin-right:0in">&nbsp;</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->unusual pain or swellings in a leg</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden severe pain in the chest, possibly radiating to the left arm</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->suddenly occurring shortness of breath,</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->a sudden coughing bout,</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->unusually severe or persistent headache,</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden partial or complete loss of vision,</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->diplopia,</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->slurred speech or aphasia,</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->vertigo,</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->collapse with or without focal seizure,</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden weakness or marked numbness in one half or part of the body,</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->disorders of the motor functions,</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&ldquo;acute&rdquo; abdomen.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Tumor diseases</em></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Breast</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">A metaanalysis involving 54 epidemiological studies pointed to a slightly enhanced relative risk (RR= 1.24) for breast cancer occurring in women currently taking combined oral contraceptives. The enhanced risk gradually declines over the 10 years after the combined oral contraceptives are no longer used.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Since breast cancer is rare in women below the age of 40, the number of additional cases of breast cancer diagnosed in current or previous users of combined oral contraceptives is low in comparison to the overall risk.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">The risk of breast cancer being diagnosed in the users of progestogen-only preparations is probably of the same order of magnitude as that determined in connection with combined oral contraceptives. It must be borne in mind, however, that any indications in respect of progestogen-only preparations are based on a much smaller population of users and are therefore less conclusive than those concerning combined oral contraceptives. These studies do not provide any evidence of a causal link.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">The findings may be due to a timelier diagnosis, the actual effects of the hormonal contraceptives, or a combination of both.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">In women who took oral contraceptives it appears that the developmental stage of any breast cancer diagnosed was clinically less advanced than cancer diagnosed in nonusers.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Liver</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">In rare cases benign liver tumors, and even more rarely malignant liver tumors, were reported in women taking oral contraceptives. In isolated cases these tumors led to life-threatening hemorrhages in the abdominal cavity. Differential diagnosis should include hepatic tumors if severe upper abdominal pain, liver enlargement or signs of intraabdominal hemorrhage occur in women on oral contraceptives.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Other diseases</em></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">In general progestogen-only preparations appear to have no effect on blood pressure in normotensive women. If, however, a persistent rise in blood pressure should develop during the use of Microlut, the latter should be discontinued.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Likewise, a recurrence of cholestatic icterus and/or cholestasis-conditioned pruritus that occurred in a previous pregnancy or during earlier use of steroidal sex hormones make it necessary to stop using Microlut.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Since Microlut may have an influence of peripheral insulin resistance and glucose tolerance, diabetics and any women who had diabetes mellitus during a past pregnancy must be closely monitored, especially in the initial period of use of this drug.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt">Depressed mood and depression are well-known undesirable effects of hormonal contraceptive use (see section&nbsp;4.8). Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide. Women should be advised to contact their doctor in the event of mood changes or depressive symptoms, including shortly after initiating treatment.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Chloasma may occur on occasions, especially in women with a history of <em>chloasma gravidarum</em>. Women who are susceptible to this should therefore not expose themselves to direct sunlight or ultraviolet light when taking Microlut.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Ectopic pregnancy</em></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Ectopic pregnancies occur more frequently in users of Microlut than in users of combined oral contraceptives. For this reason Microlut should only be used by women with a history of extrauterine pregnancy or tubal deficiency (e.g. in the case of present or past salpingitis or if only one tube is present) after carefully analyzing the risks and benefits.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">If pain in the lower abdomen occurs with an irregular cycle (amenorrhea or amenorrhea followed by continuous bleeding), the possibility of an ectopic pregnancy must be considered.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:70.9pt; margin-right:0in; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Persisting ovarian follicle</em></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">During the use of Microlut persisting ovarian follicles (often also called functional ovarian cysts) may occur. The majority of these follicles remain without symptoms, but some may be accompanied by pain in the lower abdomen or dyspareunia. In most cases these enlarged follicles disappear of their own accord during two to three months of observation.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Impaired efficacy</u></em></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">The efficacy of Microlut may be impaired, if<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p style="margin-left:63.8pt; margin-right:0in; text-indent:-14.15pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->one or several tablets are missed or taken late (see section 4.3)</p><p style="margin-left:63.8pt; margin-right:0in; text-indent:-14.15pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->vomiting or severe diarrhea occurs (see section 4.4),</p><p style="margin-left:63.8pt; margin-right:0in; text-indent:-14.15pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->if certain other drugs are taken at the same time (see section 4.5),</p><p style="margin-left:63.8pt; margin-right:0in; text-indent:-14.15pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp; If Microlut and preparations containing St-John&rsquo;s wort are taken at the same time (see section 4.5).</p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Cycle disturbances</u></em></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:67.65pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Cyclical bleeding</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">In the majority of all cases bleeding is cyclical and at normal intervals, of normal duration and intensity. Nevertheless, shorter or longer intervals have also been observed.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">For this reason the user should be informed before she starts taking the tablets that such changes in bleeding patterns are possible. The changes mainly occur in the initial months of use. Later on during use the bleeding pattern settles down and in most cases an individual pattern is established. The user should be instructed to note all bleeding occurrences in a calendar.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:67.65pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->What to do in the case of intermenstrual bleeding</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Intermenstrual bleeding of varying intensity can occur, especially in the initial months. From the medical point of view this is no reason to stop taking Microlut, provided organic reasons for such bleeding can be ruled out by suitable diagnostic means.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">No attempt should be made to treat cyclical disturbances by administering additional estrogen. Such an approach would lead to a reversal of the changes in the cervical mucus brought about by Microlut, thus considerably jeopardizing contraceptive reliability.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:67.65pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If cyclical bleeding fails to occur</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">In some women amenorrhea may occur, but in most cases this lasts only one or two cycles. In rare cases the amenorrhea may persist for longer periods.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">If bleeding fails to occur again within six weeks from the last bleeding, pregnancy must be ruled out before further tablets are taken.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt; margin-right:0in">Please note: The information regarding prescribing the relevant medicinal products should be reviewed for possible interactions.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in"><em>Influence of other medications on Microlut</em><br />There may be interactions with medicinal products inducing microsomal enzymes. This may result in an enhanced clearance of sexual hormones and breakthrough bleeding and/or loss of contraceptive efficacy.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Enzyme induction can already be observed after a few days of treatment. The maximum enzyme inducing effect is usually observed within a few weeks. After the end of therapy, the enzyme inducing effect may continue for up to 4&nbsp;weeks.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Short-term treatment</p><p style="margin-left:49.65pt; margin-right:0in">Women treated with liver enzyme inducing medicinal products should temporarily use a barrier method or another contraceptive method in addition to Microlut. The barrier method must be used for the entire duration of the concomitant use of the medicinal products and for up to 28&nbsp;days after the end of treatment.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Long-term treatment</p><p style="margin-left:49.65pt; margin-right:0in">For women receiving long-term treatment with liver enzyme inducing medicinal products, a different reliable non-hormonal contraception is recommended.</p><p style="margin-left:49.65pt; margin-right:0in"><em>Substances increasing the clearance of levonorgestrel (decreased efficacy of Microlut due to enzyme induction) such as:</em></p><p style="margin-left:49.65pt; margin-right:0in">Phenytoin, barbiturates, primidone, carbamazepine, rifampicin and possibly also oxcarbazepine, topiramate, felbamate, griseofulvin, and plant-based drugs containing St. John&rsquo;s wort (<em>Hypericum perforatum</em>).</p><p style="margin-left:49.65pt; margin-right:0in"><em>Substances with different effects on the clearance of levonorgestrel</em></p><p style="margin-left:49.65pt; margin-right:0in">When co-administered with sexual hormones, many HIV/HCV protease inhibitors and non-nucleoside reverse-transcriptase inhibitors as well as combinations of the two may increase or decrease plasma levels of the progestogen. The total effect of these changes may in some cases be clinically relevant.</p><p style="margin-left:49.65pt; margin-right:0in">Therefore, the professional datasheets for the concomitantly prescribed HIV/HCV drugs should be reviewed for possible interactions and relevant recommendations. If in doubt, women should use an additional barrier method for contraception during therapy with protease inhibitors or non-nucleoside reverse-transcriptase inhibitors.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in"><em>Substances decreasing the clearance of levonorgestrel (enzyme inhibitors)</em></p><p style="margin-left:49.65pt; margin-right:0in">Potent and moderate CYP3A4 enzyme inhibitors such as azole antifungal drugs (e.g., fluconazole, itraconazole, ketoconazole, voriconazole), verapamil, macrolide antibiotics (e.g., clarithromycin, erythromycin) and grapefruit juice may increase the plasma concentration of levonorgestrel.</p><p style="margin-left:49.65pt; margin-right:0in">The clinical relevance of potential interactions with enzyme inhibitors remains unclear.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in"><em>Influence of Microlut on other medications</em></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Oral contraceptives may influence the metabolism of specific other medicinal products. Consequently the plasma and tissue levels (e.g. of cyclosporin) can be impaired.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Note: You should refer to the professional datasheet of the respective concomitant medication for any possible interactions.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Other forms of interactions</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in"><em>Laboratory tests<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></em></p><p style="margin-left:49.6pt; margin-right:0in">The use of hormonal contraceptives may impair certain laboratory test findings, including biochemical parameters for hepatic, thyroid, adrenal and renal functions as well as plasma levels of (vector) proteins, e.g. of corticosteroid-binding globulin and of lipid/lipoprotein fractions, parameters for carbohydrate metabolism and coagulation and fibrinolysis parameters. These changes, however, generally remain within the normal range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt; margin-right:0in"><em>Pregnancy</em></p><p style="margin-left:49.65pt; margin-right:0in">Microlut is not indicated during pregnancy.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">If pregnancy occurs whilst taking Microlut, the drug product must be discontinued immediately.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Data from a limited number of pregnancies exposed {to this drug} show no deleterious effects on the fetus for levonorgestrel on its own.</p><p style="margin-left:49.65pt; margin-right:0in">Animal experimental studies have demonstrated reproduction toxicity (see section 5.3)</p><p style="margin-left:49.65pt; margin-right:0in">Undesired hormonal effects on the development of urogenital tract cannot be completely ruled out, but most of the epidemiological studies carried out to date do not indicate any enhanced risk of deformities occurring in the offspring of mothers who took contraceptives prior to pregnancy, nor are there any indications of an embryotoxic or teratogenic effect coming about through accidental ingestion of progestogens at doses like those contained in Microlut during pregnancy.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in"><em>Lactation</em></p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">During lactation hormonal contraceptives are not recommended as the method of choice for contraception. After the nonhormonal methods progestogen-only preparations are regarded as the next best choice for contraception.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">If progestogen-only preparations are used six weeks after the birth, there appear to be no detrimental effects on the growth and development of the breastfed infant. There is no evidence to suggest that progestogen-only preparations impair either quality or quantity of breast milk, although small amounts of the active substance are excreted with the milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.6pt; margin-right:0in">Microlut has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt; margin-right:0in">Summary of the side effect profile:</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">The most frequently reported side effects in association with taking Microlut are vaginal/uterine bleeding including spotting, menorrhagia and/or metrorrhagia and amenorrhea. They occur in &gt;&nbsp;10&nbsp;% of users.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">In the assessment of side effects the following frequency brackets are used:</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Very common &nbsp;&nbsp;&nbsp;&nbsp; (&ge; 10 %)</p><p style="margin-left:49.65pt; margin-right:0in">Common &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge; 1 % and &lt; 10 %)</p><p style="margin-left:49.65pt; margin-right:0in">Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge; 0.1 % and &lt; 1 %)</p><p style="margin-left:49.65pt; margin-right:0in">Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge; 0.01 % and &lt; 0.1 %)</p><p style="margin-left:49.65pt; margin-right:0in">Very rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&lt; 0.01 % or unknown)</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">The following side effects have been reported after the taking of Microlut.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><thead><tr><td style="vertical-align:top; width:109.45pt"><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top; width:363.95pt"><p style="margin-left:0in; margin-right:0in; text-align:center"><strong>Incidence of side effect</strong></p></td></tr><tr><td style="vertical-align:top; width:109.45pt"><p style="margin-left:0in; margin-right:0in"><strong>Body system</strong></p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:70.55pt"><p style="margin-left:0in; margin-right:0in"><strong>Very common</strong></p><p style="margin-left:0in; margin-right:0in"><strong>&ge;&nbsp;10&nbsp;%</strong></p></td><td style="vertical-align:top; width:84.0pt"><p style="margin-left:0in; margin-right:0in"><strong>Common</strong></p><p style="margin-left:0in; margin-right:0in"><strong>&ge; 1 % - &lt;&nbsp;10 %</strong></p></td><td style="vertical-align:top; width:102.0pt"><p style="margin-left:0in; margin-right:0in"><strong>Uncommon</strong></p><p style="margin-left:0in; margin-right:0in"><strong>&ge; 0.1&nbsp;% - &lt;&nbsp;1 %</strong></p></td><td style="vertical-align:top; width:107.4pt"><p style="margin-left:0in; margin-right:0in"><strong>Rare</strong></p><p style="margin-left:0in; margin-right:0in"><strong>&ge; 0,01&nbsp;% - &lt;&nbsp;0,1&nbsp;%</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top; width:109.45pt"><p style="margin-left:0in; margin-right:0in">Immune system disorders</p></td><td style="vertical-align:top; width:70.55pt"><p style="margin-left:0in; margin-right:-3.55pt">&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p style="margin-left:0in; margin-right:-3.55pt">&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p style="margin-left:0in; margin-right:-3.55pt">&nbsp;</p></td><td style="vertical-align:top; width:107.4pt"><p style="margin-left:0in; margin-right:0in">hypersensitivity reactions</p></td></tr><tr><td style="vertical-align:top; width:109.45pt"><p style="margin-left:0in; margin-right:0in">Psychiatric conditions</p></td><td style="vertical-align:top; width:70.55pt"><p style="margin-left:0in; margin-right:-3.55pt">&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p style="margin-left:0in; margin-right:-3.55pt">depressive moods, changes in libido</p></td><td style="vertical-align:top; width:102.0pt"><p style="margin-left:0in; margin-right:-3.55pt">&nbsp;</p></td><td style="vertical-align:top; width:107.4pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109.45pt"><p style="margin-left:0in; margin-right:0in">Nervous system disorders</p></td><td style="vertical-align:top; width:70.55pt"><p style="margin-left:0in; margin-right:-3.55pt">&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p style="margin-left:0in; margin-right:-3.55pt">headache, dizziness, nervousness</p></td><td style="vertical-align:top; width:102.0pt"><p style="margin-left:0in; margin-right:-3.55pt">&nbsp;</p></td><td style="vertical-align:top; width:107.4pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109.45pt"><p style="margin-left:0in; margin-right:0in">Ophthalmic conditions</p></td><td style="vertical-align:top; width:70.55pt"><p style="margin-left:0in; margin-right:-3.55pt">&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p style="margin-left:0in; margin-right:-3.55pt">&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p style="margin-left:0in; margin-right:-3.55pt">&nbsp;</p></td><td style="vertical-align:top; width:107.4pt"><p style="margin-left:0in; margin-right:0in">poor tolerance of contact lenses</p></td></tr><tr><td style="vertical-align:top; width:109.45pt"><p style="margin-left:0in; margin-right:0in">Gastrointest&shy;inal disorders</p></td><td style="vertical-align:top; width:70.55pt"><p style="margin-left:0in; margin-right:-3.55pt">&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p style="margin-left:0in; margin-right:-3.55pt">nausea, vomiting</p></td><td style="vertical-align:top; width:102.0pt"><p style="margin-left:0in; margin-right:-3.55pt">&nbsp;</p></td><td style="vertical-align:top; width:107.4pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109.45pt"><p style="margin-left:0in; margin-right:0in">Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:70.55pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p style="margin-left:0in; margin-right:0in">acne</p></td><td style="vertical-align:top; width:102.0pt"><p style="margin-left:0in; margin-right:0in">chloasma</p></td><td style="vertical-align:top; width:107.4pt"><p style="margin-left:0in; margin-right:0in">hirsutism, skin diseases</p></td></tr><tr><td style="vertical-align:top; width:109.45pt"><p style="margin-left:0in; margin-right:0in">Disorders of the sex organs and mammary gland</p></td><td style="vertical-align:top; width:70.55pt"><p style="margin-left:0in; margin-right:0in">bleeding disturbances such as spotting, intermenstrual bleeding or amenorrhea</p></td><td style="vertical-align:top; width:84.0pt"><p style="margin-left:0in; margin-right:0in">breast pain,<br />breast tension,<br />dysmenorrhea, vaginitis, menorrhagia*, metrorrhagia*</p></td><td style="vertical-align:top; width:102.0pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td style="vertical-align:top; width:107.4pt"><p>changes in vaginal secretion</p></td></tr><tr><td style="vertical-align:top; width:109.45pt"><p style="margin-left:0in; margin-right:0in">General diseases</p></td><td style="vertical-align:top; width:70.55pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p style="margin-left:0in; margin-right:0in">fluid retention in the tissues</p></td><td style="vertical-align:top; width:107.4pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:109.45pt"><p style="margin-left:0in; margin-right:0in">Checkups</p></td><td style="vertical-align:top; width:70.55pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p></td><td style="vertical-align:top; width:107.4pt"><p style="margin-left:0in; margin-right:0in">changes in body weight</p></td></tr></tbody></table><p style="margin-left:12.0pt; margin-right:0in">The most suitable MedDRA term has been used to describe a specific reaction, its symptoms and related conditions.</p><p style="margin-left:12.0pt; margin-right:0in">* applies generally to all progestogen-only preparations</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">See section 4.4 for further serious side effects, such as thromboembolic diseases, hepatic tumors, cervical and breast cancer.</p><p style="margin-left:48.0pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Ectopic pregnancies occur more frequently in users of hormonal contraceptives that contain a progestogen only (so-called POPs) than in users of combined oral contraceptives (see section 4.2).</p><p style="margin-left:49.65pt; margin-right:0in">During the use of Microlut persisting ovarian follicles (often also called functional ovarian cysts) may occur (see section&nbsp;4.2).</p><p style="margin-left:49.65pt"><u>&nbsp;</u></p><p style="margin-left:49.65pt"><u>Reporting of suspected adverse reactions</u></p><p style="margin-left:49.65pt; margin-right:0in">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to:</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt"><strong>&nbsp;</strong></p><p style="margin-left:49.65pt"><strong>&nbsp;</strong></p><p style="margin-left:49.65pt"><strong>To report any side effect(s):</strong></p><p style="margin-left:49.65pt">The National Pharmacovigilance Centre (NPC).</p><p style="margin-left:49.65pt">SFDA Call Center: 19999</p><p style="margin-left:49.65pt">E-mail: npc.drug@sfda.gov.sa</p><p style="margin-left:49.65pt; margin-right:0in">Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt; margin-right:0in">There have been no reports of any serious damage to health caused by an overdose.</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">The symptoms that may occur in such a case include: nausea, vomiting and mild vaginal bleeding. There is no special antidote. Treatment should be symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt; margin-right:0in">Pharmacotherapeutic category: Progestogens,</p><p style="margin-left:49.65pt; margin-right:0in">ATC code: G03AC03</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">Microlut contains the orally effective progestogen levonorgestrel at a very low dose.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">The continuous daily ingestion of 30 &micro;g levonorgestrel prevents conception by various separate mechanisms.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">Microlut mainly acts via its peripheral progestogenic effect on cervical mucus, the tubes and the endometrium. This prevents ascension of the sperms as well as disturbing the transport and implantation of the ovum. Ovulation is inhibited in few women. Microlut impairs the gonadotropin peak in the middle of the cycle and the corpus luteum function, which can also contribute to the contraceptive effect.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">POPs are particularly suitable for women in whom estrogens are contraindicated or not desired, and also for breastfeeding women starting six weeks after childbirth.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">The contraceptive reliability of POPs is somewhat lower than with combined oral contraceptives. If taken properly, the risk of becoming pregnant is however very low, comparatively speaking.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">In clinical studies in which 3,218 women took<strong> </strong>Microlut for up to two years, involving 28,000 menstrual cycles, 90 pregnancies occurred. Taking all these pregnancies into account, including those occasioned by incorrect tablet-taking, the Pearl Index for Microlut amounts to 4.14.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt"><em>Absorption</em></p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">Levonorgestrel is rapidly and almost completely absorbed on oral administration. A peak serum level of about 0.8 ng active substance per mL is reached about one hour after administration of 30 &micro;g levonorgestrel (Microlut).</p><p style="margin-left:49.65pt">Absolute bioavailability of levonorgestrel from Microlut<sup> </sup>is 82&nbsp;%.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt"><em>Distribution</em></p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">Levonorgestrel is bound to serum albumin and sex hormone binding globulin (SHBG). Only approx. 1.5&nbsp;% of the total levonorgestrel serum concentration is in the form of free levonorgestrel; approx. 65 % is specifically bound to SHBG. The relative distribution of serum levonorgestrel (free, albumin-bound and SHBG-bound) depends on the actual level of SHBG. Upon ingestion of Microlut the serum level of SHBG may fall slightly, and this will have a slight effect on the relative distribution of levonorgestrel with respect to the two binding proteins.</p><p style="margin-left:49.65pt">The apparent volume of distribution of levonorgestrel is approx. 106 L.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">Levonorgestrel passes into the mother&rsquo;s milk. About 0.1 % of the maternal dose can be transferred to the infant during breastfeeding.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt"><em>Special patient groups</em></p><p style="margin-left:49.65pt">Serum levonorgestrel concentrations decrease with increasing body weight. According to a population pharmacokinetics analysis, mean levonorgestrel concentrations fell from approximately 288-379&nbsp;ng/L at a body weight of 55&nbsp;kg to values of 196-264&nbsp;ng/L at a body weight of 80&nbsp;kg, depending on baseline SHBG levels (range from 50&nbsp;to 100&nbsp;nmol/L).In women with a relatively high body weight, the mean levonorgestrel concentration fell still further: in women weighing 45&nbsp;kg and women weighing 90&nbsp;kg, there was an approximately two-fold difference in the levonorgestrel concentrations. In the absence of relevant data, the influence of reduced serum LNG on contraceptive efficacy currently cannot be quantified.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt"><em>Biotransformation</em></p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">Levonorgestrel is extensively metabolized. The most important biotransformation pathways are &Delta;4-3-oxo group reduction and hydroxylation at positions 2&alpha;, 1&beta; and 16&beta;, followed by conjugation. CYP3A4 is the principal enzyme involved in oxidative LNG metabolism. However, <em>in&nbsp;vitro</em> data indicate that CYP-dependent biotransformation reactions are less relevant for levonorgestrel than reduction and conjugation. There are no known pharmacologically active metabolites.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">The metabolic clearance rate from serum is between 1 and 1.5 mL/min/kg.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt"><em>Elimination</em></p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">Levonorgestrel serum levels fall in two phases, characterized by half-lives of about one hour and 20 hours respectively.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">Elimination of the metabolites is roughly equally shared between the urine and feces. Metabolite elimination half-life is about one day.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt"><em>Steady-state conditions</em></p><p style="margin-left:49.65pt">&nbsp;</p><p>After repeated daily ingestion of levonorgestrel serum levels roughly double and reach steady-state conditions after about five days. The pharmacokinetic properties of levonorgestrel are influenced by the serum levels of SHBG. A daily intake of 0.150 mg levonorgestrel (equivalent to five times the daily dose of Microlut) leads to a 50% drop in SHBG serum levels and to a 40% fall in the trough levels of levonorgestrel after two to three weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt">The toxicity profile of levonorgestrel is well known. In animal experiments levonorgestrel demonstrated an embryolethal effect and at high doses a virilization effect on female fetuses. Reproduction toxicological studies in rats, mice and rabbits showed no signs of a teratogenic effect. On the strength of conventional studies into safety pharmacology, toxicity after repeated dosage, reproduction toxicology, genotoxicity and carcinogenic potential the preclinical findings reveal no special risk to humans aside from the information already listed in other sections. On the other hand it must be remembered that sex hormones can promote the growth of hormone-dependent tissue and tumors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt; margin-right:0in">Tablet core:</p><p style="margin-left:49.65pt; margin-right:0in">lactose monohydrate,</p><p style="margin-left:49.65pt; margin-right:0in">Maize starch,</p><p style="margin-left:49.65pt; margin-right:0in">Polyvidone K 25,</p><p style="margin-left:49.65pt; margin-right:0in">Talc,</p><p style="margin-left:49.65pt; margin-right:0in">Magnesium stearate (Ph.Eur.)</p><p style="margin-left:49.65pt; margin-right:0in">&nbsp;</p><p style="margin-left:49.65pt; margin-right:0in">Tablet coating:</p><p style="margin-left:49.65pt; margin-right:0in">Sucrose,</p><p style="margin-left:49.65pt; margin-right:0in">Polyvidone K 90,</p><p style="margin-left:49.65pt; margin-right:0in">Macrogol 6000,</p><p style="margin-left:49.65pt; margin-right:0in">Calcium carbonate,</p><p style="margin-left:49.65pt; margin-right:0in">Talc</p><p style="margin-left:49.65pt; margin-right:0in">Montanglycol wax</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt; margin-right:0in">not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt; margin-right:0in">Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt">Blister pack (PVC/aluminum) containing 35 coated tablets in a folding box.</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">Pack containing one blister pack containing 35 coated tablets</p><p style="margin-left:49.65pt">Pack containing three blister packs, each containing 35 coated tablets</p><p style="margin-left:49.65pt">&nbsp;</p><p style="margin-left:49.65pt">Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:49.65pt; margin-right:0in">No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG
51368 Leverkusen
Germany 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>